Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Heron Therapeutics, Inc. (HRTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed commercial-stage biotechnology company, Heron uses Forms 10‑K, 10‑Q, 8‑K, and proxy statements on Schedule 14A to report financial results, material events, and governance matters related to its acute care and oncology supportive care business.
Investors reviewing HRTX SEC filings can examine current reports on Form 8‑K that disclose items such as quarterly and year‑to‑date financial results, capital restructuring transactions, amendments to credit facilities with Hercules Capital, Inc., exchange and issuance of convertible senior unsecured promissory notes, private placements of common and preferred equity, and adoption of a Tax Benefit Preservation Plan intended to protect net operating loss carryforwards. Other 8‑K filings describe material agreements, manufacturing and supply arrangements with Patheon, office lease commitments for corporate headquarters, and changes in the composition of the Board of Directors.
Heron’s proxy statements on Schedule 14A provide detail on stockholder meetings, including special meetings to approve the issuance of common stock upon conversion of convertible notes and Series A Convertible Preferred Stock under Nasdaq Listing Rule 5635(d). These documents explain voting procedures, virtual meeting logistics, and the specific proposals presented to stockholders.
Through this page, users can also track governance and capital structure disclosures such as the creation of Series A Convertible Preferred Stock and Series B Preferred Stock, rights plans, and cooperation agreements with significant investors. Stock Titan enhances these filings with AI‑powered summaries that highlight key terms, financial implications, and governance changes, helping readers quickly understand complex agreements without replacing the full legal text. Real‑time updates from EDGAR ensure that new HRTX filings, including 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available, are surfaced promptly for further analysis.
Heron Therapeutics, Inc. filed a current report to share that it has issued a press release with preliminary financial results for the three months ended December 31, 2025 and for full-year 2025. The company furnished this press release as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is being provided for informational purposes and is not treated as formally filed for liability purposes under Section 18 of the Exchange Act. The company also notes that this information will only be incorporated into other securities filings if specifically referenced.
Heron Therapeutics (HRTX)37,879 shares of common stock via restricted stock units, with 37,879 shares beneficially owned following the transaction. Each RSU equals one share and vests in 16 equal quarterly installments beginning one quarter after grant.
On the same date, the director received stock options for 227,272 shares at an exercise price of $1.1, expiring on 11/08/2035. These options vest in 48 equal monthly installments starting one month after grant.
Heron Therapeutics (HRTX) reported an initial statement of beneficial ownership on Form 3 for director Thomas P. Cusack. The filing states that, as of the event date 10/27/2025, no securities are beneficially owned.
The report indicates it was filed by one reporting person and lists no non-derivative or derivative holdings, with the explanation: “No securities are beneficially owned.” The signature is provided by an attorney-in-fact on behalf of the reporting person.
Heron Therapeutics (HRTX): Officer William P. Forbes reported an RSU vesting and settlement. On 10/31/2025, 11,694 shares of common stock were acquired from restricted stock units at a price of $0.00 per share (Transaction Code M). Following this, he beneficially owned 166,203 shares directly. The filing also lists 152,027 restricted stock units remaining after the transaction.
Each restricted stock unit represents the right to receive one share of common stock. The RSUs vest in 16 equal installments beginning one quarter after the grant date, January 31, 2025.
Heron Therapeutics (HRTX) reported an insider transaction by EVP & Chief Financial Officer Ira Duarte. On 10/31/2025, 11,694 shares of common stock were acquired upon settlement of restricted stock units. After this transaction, 179,786 common shares are beneficially owned directly, and 152,027 restricted stock units remain outstanding. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Heron Therapeutics (HRTX) reported an insider transaction: CEO and Director Craig Collard acquired 34,789 shares of common stock on 10/31/2025 through settlement of restricted stock units (transaction code M) at $0.
Following the transaction, Collard directly owned 523,124 shares. He also beneficially owned 452,253 RSUs after the event. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Heron Therapeutics (HRTX) reported Q3 2025 results with net product sales of $38.2 million, up from $32.8 million a year ago. Gross profit was $26.3 million and the company posted a net loss of $17.5 million, or $0.10 per share. Cash and cash equivalents were $43.1 million, and cash plus short‑term investments totaled $55.5 million as of September 30, 2025.
Product mix showed CINVANTI at $24.0 million, ZYNRELEF $9.3 million, APONVIE $3.0 million, and SUSTOL $1.9 million. Heron refinanced its balance sheet: it amended its Hercules working capital facility to up to $150.0 million and drew $110.8 million; exchanged and extinguished $150.0 million of 2026 convertible notes (including issuing 16.67 million shares for $25.0 million of principal and paying $125.0 million in cash); and issued $35.0 million of 2031 convertible notes. It also raised $27.7 million gross via a private placement of common and Series A preferred stock. The quarter included $11.3 million in loss on debt extinguishment. Management believes its cash, cash equivalents and short‑term investments are sufficient for at least one year.
Heron Therapeutics (HRTX) furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 to this report and is provided under Item 2.02.
The company states the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under the Exchange Act. The filing date is November 4, 2025.
Heron Therapeutics (HRTX) appointed Thomas Cusack to its Board of Directors, effective October 27, 2025. He will serve until the Company’s 2026 Annual Meeting of Stockholders and join the Nominating and Corporate Governance Committee. The appointment was made pursuant to a Cooperation Agreement between the Company and Rubric Capital Management LP dated August 8, 2025.
The Company states there are no transactions involving Mr. Cusack requiring disclosure under Item 404(a). He will receive compensation under Heron’s standard program for non-employee directors as described in the April 30, 2025 proxy statement, and will enter into the Company’s standard Director Indemnification Agreement, with the form to be filed with the 2025 Form 10-K. A press release dated October 29, 2025 was furnished as Exhibit 99.1.
Heron Therapeutics (HRTX) reported an insider equity change. EVP & Chief Development Officer William P. Forbes acquired 3,874 shares of common stock on 10/19/2025 via the conversion of restricted stock units (transaction code M). Following this event, he directly owns 154,509 shares of common stock. The filing also lists 34,869 derivative securities remaining as restricted stock units. Each RSU equals one share, and the RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.